Datar Cancer Genetics
Business Services · India · 51-200 Employees
View Company Info for Free
Overview
Headquarters
F-8 D Rd, Ambad A.S., Maharashtra, 42201...Phone Number
+91 18001210700Website
www.datarpgx.comRevenue
$15 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Datar Cancer Genetics
Datar Cancer Genetics specializes in developing innovative blood-based diagnostics for early cancer detection, non-invasive treatment options, and monitoring disease progression or recurrence. The company focuses on personalized cancer management through advanced liquid biopsy technology, utilizing molecular science to enhance treatment strategies. Their target clients include patients seeking early diagnosis and effective management of cancer, as well as healthcare professionals looking for reliable diagnostic solutions. With a commitment to relentless research and innovation, Datar Cancer Genetics aims to revolutionize cancer care and improve patient outcomes.Explore more
Datar Cancer Genetics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Datar Cancer Genetics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Datar Cancer Genetics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Datar Cancer Genetics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Datar Cancer Genetics
Product Launch: Get notified when Datar Cancer Genetics launches new products
Funding: Get notified immidiatlly once Datar Cancer Genetics has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Datar Cancer Genetics had a recent Job posting/layoffs
Earning: See what the market has to say on Datar Cancer Genetics recently announced quarterly report
Datar Cancer Genetics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Datar Cancer Genetics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Datar Cancer Genetics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Datar Cancer Genetics.
Datar Cancer Genetics Tech Stack
A closer look at the technologies used by Datar Cancer Genetics
Datar Cancer Genetics News & Media
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple MyelomaDatar Cancer Genetics Receives Landmark US FDA Clearance for CellDx-Tissue, a Comprehensive Genomic Profiling Assay for Solid Tumors Using DNA + RNA
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Level Evidence NASHIK, India, May 14, 2026 /PRNewswire/ -- Datar Cancer Genetics (DCG), a global precision oncology company, today...New Study Shows Aliya® Pulsed Electric Field Ablation Achieved Local Control of Lung Tumors in Metastatic Cancer Patients and May Induce an Immune Response
Six-month results from U.S. clinical study show promise for the innovative technology in patients with stage IV non-small cell lung cancer or lung metastasis REDWOOD CITY, Calif., Nov. 11, 2025 /PRNewswire/ -- Galvanize ("Galvanize") Therapeutics, Inc., a commercial-stage medical...Merus Announces the Journal Publication of Petosemtamab Mechanism of Action
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced publication on the mechanism of action of petosemtamab, a bispecific antibody targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G (LGR5), in the scientific journal “Can
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Datar Cancer Genetics
Sign Up For FreeTo access detailed company insights
Datar Cancer Genetics specializes in developing innovative blood-based diagnostics for early cancer detection, non-invasive treatment options, and monitoring disease progression or recurrence. The company focuses on personalized cancer management through advanced liquid biopsy technology, utilizing molecular science to enhance treatment strategies.... Read More
